A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis

Trial Profile

A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 02 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016.
    • 25 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top